Better therapeutics through microarrays

Nature Genetics

Volumn 32, Issue 4S, 2002, Pages 547-552

  Gerhold, David L ^a   Jensen, Roderick V ^b   Gullans, Steven R ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WESLEYAN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; DNA MICROARRAY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; MATHEMATICAL ANALYSIS; MOLECULAR SIZE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TOXICITY; VALIDATION PROCESS;

COMPUTATIONAL BIOLOGY; DNA; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MATHEMATICS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; STATISTICS; TOXICOLOGY;

EID: 0036898203     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1042     Document Type: Review

References (40)

1. Golub, T.R. et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
2. Pomeroy, S.L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
3. Gordon, G.J. et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 62, 4963-4967 (2002).
4. Petricoin, E.F. et al. Medical applications of microarray technologies: A regulatory science perspective. Nature Genet. 32, 474-479 (2002).
5. Fryer, R.M. et al. Global analysis of gene expression: Methods, interpretation, and pitfalls. Exp. Nephrol. 10, 64-74 (2002).
6. Gerhold, D. and Caskey, C.T. It’s the genes! EST access to human genome content. BioEssays 18, 973-981 (1996).
7. Tusher, V.G., Tibshirani, R. and Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
8. Ideker, T., Thorsson, V., Siegel, A.F. and Hood, L.E. Testing for differentially-expressed genes by maximum-likelihood analysis of microarray data. J. Comput. Biol. 7, 805-817 (2000).
9. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
10. Efron, B. and Tibshirani, R. Empirical bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 23, 70-86 (2002).
11. Xu, H. and Raafat el-Gewely, M. p53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol. Annu. Rev. 7, 131-164 (2001).
12. Yang, Y. H. and Speed, T. Design issues for cDNA microarray experiments. Nature Rev. Genet. 3, 579-588 (2002).
13. Quackenbush, J. Computational analysis of microarray data. Nature Rev. Genet. 2, 418-427 (2001).
14. Eisen, M.B., Spellman, P.T., Brown, P.O. and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
15. Sarang, S.S. et al. Discovery of molecular mechanisms of neuroprotection using cell based bioassays and oligonucleotide arrays. Physiol. Genom. (2002); advance online publication 17 September 2002 (doi:10.1152/physiolgenomics. 00064.2002).
16. Butte, A.J., Tamayo, P., Slonim, D., Golub, T.R. and Kohane, I.S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA97, 12182-12186 (2000).
17. Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science275, 343-349 (1997).
18. Staunton, J.E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-10792 (2001).
19. Cho, Y.S. et al. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl Acad. Sci. USA 98, 9819-9823 (2001).
20. Hannon, G.J. RNA interference. Nature 418, 244-251 (2002).
21. Fambrough, D., McClure, K., Kazlauskas, A. and Lander, E.S. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 97, 727-741 (1999).
22. Lee, S.B. et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98, 663-673 (1999).
23. Welcsh, P.L. et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl Acad. Sci. USA 99, 7560-7565 (2002).
24. Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088-2093 (1998).
25. Hu, W.Y., Fukuda, N. and Kanmatsuse, K. Growth characteristics, angiotensin II generation, and microarray-determined gene expression in vascular smooth muscle cells from young spontaneously hypertensive rats. J. Hypertens. 20, 1323-1333 (2002).
26. Karpen, S.J. Nuclear receptor regulation of hepatic function. J. Hepatol. 36, 832-850 (2002).
27. Whitlock, J.P. Jr. and Denison, M.S. (ed.) Induction of Cytochrome P450 Enzymes that Metabolize Xenobiotics (Plenum, New York, 1995).
28. Gerhold, D. et al. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol. Genom. 5, 161-170 (2001).
29. Rodrigues, A.D. and Rushmore, T.H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr. Drug Metab. 3, 289-309 (2002).
30. Hansten, P.D. and Horn, J.R. The Top 100 Drug Interactions: A Guide to Patient Management (HandH Publications, Edmonds, WA, 2002).
31. Heimark, L.D., Gibaldi, M., Trager, W.F., O’Reilly, R.A. and Goulart, D.A. The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42, 388-394 (1987).
32. Baker, T.K. et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem. Res. Toxicol. 14, 1218-1231 (2001).
33. Waring, J.F. et al. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42 (2001).
34. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
35. Hamadeh, H.K. et al. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 67, 232-240 (2002).
36. Thomas, R.S. et al. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60, 1189-1194 (2001).
37. Burczynski, M.E. et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58, 399-415 (2000).
38. Pennie, W. D., Woodyatt, N. J., Aldridge, T. C. and Orphanides, G. Application of genomics to the definition of the molecular basis for toxicity. Toxicol. Lett. 120, 353-358 (2001).
39. Ueda, A. et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61, 1-6 (2002).
40. Wei, P., Zhang, J., Dowhan, D.H., Han, Y. and Moore, D.D. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenom. J. 2, 117-126 (2002).